RGCC Oncocount

Enhance Your Odds In The Fight Against Cancer

RGCC Oncocount is a follow-up tool for cancer patients undergoing treatment, offering insight into the effectiveness of therapies and monitoring disease progression. Circulating Tumor Cells (CTCs) serve as potent biomarkers, their presence in the bloodstream signaling a potential resurgence of cancer.

Sample Type
Whole peripheral blood sample
Sample Size
10-15ml blood
All types except CNS
Turnaround Time
21 days

How it works?

The RGCC Oncocount test serves as a monitoring tool utilized during and post-treatment to assess the effectiveness of your cancer therapy and facilitate early detection of recurrence or relapse. Enumerating circulating tumor cells (CTCs) acts as a prognostic factor, assisting clinicians in anticipating the disease progression and executing appropriate treatment approaches.

How it is done?

RGCC Oncocount test uses state-of-the-art Flow Cytometry technology to isolate the Circulating tumour Cells from the blood samples with exceptional viability rates. Circulating Tumor Cell (CTC) tests are specifically isolated using negative selection technology.
The test calculates essential indicators suchThis innovative approach ensures that all cancer cell populations are captured. By employing this comprehensive methodology, we can provide a more thorough and precise count of your CTCs, thereby offering a more reliable assessment of your cancer status. as tumor mutational burden (TMB) and microsatellite instability (MSI), providing a comprehensive view of the genetic landscape.

Why choose RGCC Oncocount?

CTCs presence: Can be used as a predictive biomarker to set the stage for further analysis, including molecular profiling, immunophenotyping, gene expression assays, and sensitivity assessments of various treatment modalities. 

CTC Concentration: Is often correlated as a prognostic indicatorHigher CTC counts are associated with poorer prognosis and increased risk of disease progression and recurrence. 

A significant decrease in CTC numbers following treatment may indicate a positive response to therapy. If the decrease in CTC count is low, it may indicate the necessity for adjustments in treatment protocols or even incorporating supplementary therapies. 

Which cancers are tested?

Oncocount used as a follow-up test offers insight into the effectiveness of cancer therapy and facilitates early detection of recurrence or relapse of several cancers.

The test applies to all types of cancers except the one in the central nervous system and is not just limited to the following.

Head & Neck Cancer
Liver Cancer
Kidney Cancer
Prostate Cancer
Pancreatic Cancer
Colon Cancer
Lung Cancer
Gastric Cancer
Colorectal Cancer
Bladder Cancer
Breast Cancer


Book an appointment

The first step towards personalized cancer care is scheduling an appointment with us.


30 minutes value packed consultation

Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.


Finding the right tests

We guide you through the process of selecting the most effective tests for your specific cancer.


Personalized results

We deliver precise results that guide treatment decisions and enhance outcomes.

Why clinicians prefer RGCC Oncocount than other similar tests?

Dr. Ameen Noorul

“RGCC’s Oncocount test is crucial for monitoring cancer recurrence and guiding long-term treatment strategies. Its precision enables proactive management, improving patient outcomes and quality of life. A vital component of comprehensive cancer care.”

Request a Second Opinion

Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.

Useful Information

A simple non-invasive test to monitor cancer.

We suggest undergoing followup tests every three months during active cancer treatment to evaluate the efficacy of the ongoing treatment plan.

Every 3 months for 1 year after completing the treatment to monitor for early relapse/recurrence. Once patients achieve full remission, the test is recommended every six months.

Start your personalized cancer journey with us!

Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.

    Frequently Asked Questions

    • Can tests be conducted during ongoing treatment?

      Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.

    • What happens to my blood sample post-testing?

      Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.

    • Is a blood sample sufficient?

      Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.

    • Can the origin of a tumor be determined by the tests?

      Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.

    • What tests are effective in identifying the emergence of secondary tumors?

      RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.

    • How do tests personalize cancer treatment?

      Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.

    • What are CTCs and CSCs?

      Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.

    • Do tests reveal drug response and sensitivity to immunotherapy?

      Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.

    Monitor CTCs for early detection!

    Detect the potential recurrence of cancer early with precise monitoring of Circulating Tumor Cells (CTCs), you can take control of your cancer journey. RGCC Oncocount empowers clinicians and patients with proactive monitoring to stay ahead in your fight against cancer.